Related Experiment Video
Updated: May 30, 2026
09:35
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Molecular mechanisms regulating hepcidin revealed by hepcidin disorders
Clara Camaschella1, Laura Silvestri
1Vita-Salute University and Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy. camaschella.clara@hsr.it
Thescientificworldjournal
|July 27, 2011
Summary
Iron regulation is vital for health, involving cellular controls and the liver peptide hepcidin. Disruptions cause iron disorders like anemia or overload, with new therapeutic targets emerging.
Area of Science:
- Biochemistry
- Molecular Biology
- Physiology
Background:
- Iron is essential for life but toxic in excess, necessitating strict homeostasis.
- Cellular iron regulation involves cytosolic iron regulatory proteins and iron-responsive elements on mRNA.
- Systemic iron balance is controlled by the liver peptide hormone hepcidin.
Purpose of the Study:
- To review the molecular mechanisms of iron homeostasis.
- To discuss genetic and acquired disorders of iron metabolism.
- To highlight potential therapeutic targets in iron disorders.
Main Methods:
- Review of existing literature on iron metabolism and regulation.
- Analysis of post-transcriptional gene control mechanisms.
- Examination of systemic regulation by hepcidin and inflammatory cytokines.
Main Results:
- Disruptions in iron regulatory pathways cause iron deficiency anemia and hemochromatosis.
- Acquired disorders like anemia of chronic disease involve iron maldistribution.
- Hepcidin regulation by iron and cytokines reveals new therapeutic avenues.
Conclusions:
- Cellular and systemic mechanisms maintain iron homeostasis.
- Dysregulation leads to significant human diseases.
- Understanding hepcidin pathways offers opportunities for novel iron disorder therapies.
More Related Videos
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
02:04Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...